Wegovy in pill form for weight loss: separating fact from assumption

The biggest myth: that the Wegovy tablet is just the injection in disguise

Most people who search for Wegovy in pill form assume they are looking for an easier version of the injection, the same dose, the same experience, just swallowed instead of injected. That is not quite right. The tablet contains semaglutide, the same GLP-1 receptor agonist found in the weekly jab, but it reaches your bloodstream through an entirely different mechanism. Without help, semaglutide is broken down in the stomach before it can be absorbed. The tablet pairs it with a compound called SNAC, which temporarily alters the stomach lining's permeability and allows the drug to cross into the bloodstream at the stomach wall rather than the gut. This is why the tablet must be taken on a completely empty stomach (first thing in the morning, with no more than a small sip of plain water) and why you need to wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. Swallow it whole. That ritual matters: even a cup of tea beforehand can blunt absorption enough to affect how well the medicine works. As a quick habit worth building: before you leave the bedroom in the morning, take the tablet, note the time on your phone, and don't head to the kitchen for half an hour. Simple, but easy to miss in a groggy morning rush.

Because the absorption route is different from the injection, the doses are not equivalent. The 25 mg maintenance tablet is not comparable to the 2.4 mg weekly injection in the way that miligram-to-miligram comparisons might suggest. They are different formulations, each with their own licensed schedule. You can read more about how the tablet works in practice on our Wegovy pill form overview.

The dose ladder, and why Rybelsus tablets are not the same thing

The licensed Wegovy tablet schedule starts at 1.5 mg and moves through 4 mg and 9 mg before reaching the 25 mg maintenance dose, with a minimum of one month at each level. A prescriber decides when to progress; the schedule is not self-directed. People who are already stable on the 2.4 mg weekly injection may be able to move directly to the 25 mg tablet, but only following clinical assessment, that transition is not automatic.

One confusion that comes up repeatedly: some readers find references to oral semaglutide tablets at 3 mg, 7 mg and 14 mg and assume these are steps on the Wegovy weight-loss ladder. They are not. Those are the strengths of Rybelsus, a different oral semaglutide product licensed for type 2 diabetes, not weight management. The two products share an active ingredient but have different licensed indications, different dose ranges and different MHRA approvals. If you have been reading about semaglutide tablets for weight loss and stumbled across the 3 mg or 7 mg figures, they refer to the diabetes medicine. The weight-loss tablet's steps are 1.5, 4, 9 and 25 mg, that is the complete list.

Storage is genuinely straightforward. Unlike the injection, which needs to stay refrigerated between 2 and 8°C, the Wegovy tablet can be kept at room temperature. For practical detail on living with the tablet day to day, our Wegovy weight-loss tablets page covers what to expect.

What the trial evidence actually says, and how to read it honestly

The MHRA approval was supported by the OASIS 4 phase-3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks, alongside lifestyle changes. Average weight loss across all participants taking the tablet was around 13.6%, compared with roughly 2.4% in the placebo group. Among participants who adhered fully to the treatment protocol throughout, the average was close to 17%. Both figures come from the same trial; the 17% applies specifically to the adherent subgroup, so it should always be read that way rather than as the headline average.

Gastrointestinal side effects were common in the trial, around 74% of participants on the tablet reported them at some point, compared with 42% in the placebo group. Nausea, vomiting, diarrhoea and constipation are the most typical, and they tend to be most noticeable at the start of each dose step, easing as the body adjusts. For a fuller breakdown of what people commonly experience, the Wegovy pill page goes into more detail, and the NHS medicines page for semaglutide lists recognised effects with plain-language guidance on when to seek help.

The MHRA's approval announcement on 11 June 2026 described the tablet as the first oral GLP-1 medicine licensed in the UK for weight management, and the UK was the first in Europe to grant that authorisation. The full prescribing information is held in the Summary of Product Characteristics published on the electronic Medicines Compendium, the most authoritative place to check dosing and safety detail. A NICE appraisal has not yet taken place, which means the tablet is not currently available on the NHS; it requires a private prescription at this stage.

Who can be prescribed the Wegovy tablet, and the route to a prescription

The MHRA licence covers adults with a BMI of 30 or above, or adults with a BMI between 27 and 29.9 who have at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or pre-diabetes, alongside a reduced-calorie diet and increased physical activity. BMI alone does not determine eligibility; a prescriber looks at the whole clinical picture, including other medicines, medical history and the appropriateness of a GLP-1 medicine for that individual.

The tablet is not suitable in pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. Certain conditions, including a personal or family history of medullary thyroid carcinoma, require a conversation with a specialist before treatment could be considered. These exclusions are part of why a clinical assessment is required, the prescription process exists to check these factors, not to create unnecessary friction. Our oral Wegovy for weight loss page covers the assessment process in more detail, and the Wegovy pill UK where to buy page addresses the legitimate supply routes and what to look for when choosing a pharmacy.

For anyone exploring whether the tablet or the injection suits them better, both options are part of what our prescribers discuss at consultation. The weight-loss treatment overview gives a broader picture of what is available, and the FAQs cover the questions that come up most often at that stage. If you are ready to have that conversation, you can speak to our prescribers by starting a free consultation at our treatment page, the assessment is thorough, free, and reviewed the same day by a real clinician.